Frank Washkuch
Verified
As seen in:
Haymarket Media,
PR Week,
The PR Week,
Campaign (UK),
Campaign (US),
MM+M,
PR Week UK,
Campaign Asia,
The Chestnut Post,
Campaign (Canada)
Executive editor @ PRWeek, content farmer, loud typer, mentality monster. Pitches? frank.washkuch@haymarketmedia.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Frank Washkuch
Laid off? A 5-step survival guide for navigating the Omnicom deal and AI disruption
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription options.
John Wren: Omnicom 'very happy' with PR services as new holding company takes shape
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription options.
Pfizer’s Sally Susman to step down at year’s end amid broader restructuring
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription options.
The PR Week: 7.13.2023 - Doug Thornell, SKDK
Trending : Power List Cannes 2023 Gen Zeitgeist Agency Business Report Purpose Awards Thornell talks about his first half-year leading the DC-based firm and much more. Sign in to continue Sign in Sign in Email address Password Stay signed in Register Don't have an account?
Breakfast Briefing: 5 things for PR pros to know on Tuesday morning
New MSL US health MD; Dentsu restructuring; CVS Health’s big home healthcare bet. by Frank Washkuch Sign in to continue Register Don't have an account?
Five things for pharma marketers to know: Wednesday, August 8, 2018
President Donald Trump said he is planning an announcement next week that will bring down the price of prescription drugs “really, really substantially.” However, Trump didn't further explain his plans at a dinner with corporate leaders at his Bedminster, New Jersey, golf club. (Bloomberg) CVS Health topped analysts' estimates for profit and revenue in Q2. The company's revenue from retail pharmacies increased by 5.7% to $20.7 billion, with pharmacy revenue up by 8.3%.
Five things for pharma marketers to know: Monday, July 16, 2018
The FDA on Friday approved the first treatment for smallpox in case the virus is used in a terrorist attack. The disease was eradicated in 1980, but people born since then haven't been vaccinated. SIGA Technologies has delivered 2 million treatments of the drug, TPOXX, for stockpiling by the government. (Associated Press) While partnering with Berkshire Hathaway and JP Morgan Chase on healthcare costs, Amazon could also improve wellness by improving the way people eat, according to experts.
Five things for pharma marketers to know: Wednesday, July 11, 2018
Pfizer is planning to split into three business units: innovative medicines, established medicines, and consumer healthcare, with the innovative medicines group including biosimilars and a newly created hospital unit. The company is currently divided into two units: innovative medicines and essential health. (Reuters) Pfizer said on Tuesday that it is planning to hold off on recently announced price increases, shortly after President Donald Trump criticized the decision on Twitter.
Five Agency 100 things for pharma marketers to know: Monday, July 9, 2018
It's time for MM&M's biggest issue of the year, and the most comprehensive guide to the pharma marketing agency world: the Agency 100. This year's report is focused on the new agency world, with an in-depth look at how firms are resetting their priorities to stay ahead of the game. By the numbers: Is your firm keeping up with the Joneses, or make that the Kick Healths and McCann Healths of the world?
Five things for pharma marketers to know: Friday, July 6, 2018
Shares of Biogen were up sharply on Friday after its BAN2401 Alzheimer's treatment showed positive results in a large clinical trial. The 18-month trial of the drug, made by Biogen and Japanese pharma company Eisai, surprised investors after a 12-month trial failed last December. (Bloomberg) Two-thirds of analysts reached by Thomson Reuters recommend AstraZeneca's stock, just one year after the failure of a key cancer drug caused its largest single-day share-price drop.
Five things for pharma marketers to know: Thursday, July 5, 2018
Amazon could be selling prescription drugs through recently acquired internet pharmacy PillPack sooner rather than later, according to experts who cite previous Amazon deals as examples. For instance, customers were able to take advantage of Amazon promotions at Whole Foods the day its acquisition of the grocery chain closed. (CNBC). The Trump administration has named Uttam Dhillon as head of the Drug Enforcement Administration. Dhillon most recently served as deputy White House counsel.
Montefiore's Corazon - Give Your Heart campaign wins Health & Wellness Grand Prix
The Corazon - Give Your Heart campaign from Montefiore, a short film encouraging organ donation, won the Grand Prix in the Health & Wellness Lions on Monday. The campaign was entered by John X. Hannes in New York.
Five things for pharma marketers to know: Thursday, June 7, 2018
Bayer has finally closed its $63 billion acquisition of Monsanto after a two-year antitrust review. The deal makes Bayer the largest developer of seed and agricultural chemicals in the world. The companies are set to begin combining operations in two months, with the merged company based in Monheim, Germany. (Bloomberg) Warren Buffett, Jamie Dimon, and Jeff Bezos have picked an executive to run their healthcare partnership.
Five things for pharma marketers to know on Wednesday, May 23, 2018
Merck's Keytruda cancer treatment succeeded in extending survival and preventing disease progression when paired with chemotherapy in a late-stage study, the company said on Wednesday. The drug met its goals when compared with just chemotherapy. (Reuters) Astellas is planning to cut 600 positions through an early retirement program, part of CEO Kenji Yasukawa's plan to restructure the company. Astellas is planning to reorganize R&D and sales and marketing, as well as its group companies in Japan.
Show More
loading
Actions
Get in touch with Frank
Contact Frank, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack